Is RMTI or RNAZ more undervalued in 2026?

CirclFi compares Rockwell Medical, Inc. (RMTI) and TransCode Therapeutics, Inc. (RNAZ) using 13 institutional-grade valuation models. RMTI has a Quality of Company score of 6.0/10 while RNAZ scores 3.9/10.

Which is a better buy — RMTI or RNAZ?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RMTI and RNAZ valuations compare?

RMTI at $0.74 and RNAZ at $5.14 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RMTI vs RNAZ Valuation Comparison 2026 — Intrinsic Value Analysis

RMTI

Pharmaceutical Preparations

Rockwell Medical, Inc.

Quality

6.0

out of 10

Value Trap

SAFE

Price

$0.74

Last close

Models

11/13

Active

RNAZ

Pharmaceutical Preparations

TransCode Therapeutics, Inc.

Quality

3.9

out of 10

Value Trap

LOW

Price

$5.14

Last close

Models

6/13

Active

Model-by-Model Comparison

Model	Type	RMTI Fair Value	RMTI Upside	RNAZ Fair Value	RNAZ Upside
Bayesian DCF	Intrinsic	$0.22	-69.8%	$9.29	+80.8%
Earnings Power Value	Intrinsic	$0.19	-77.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$1.05	+40.7%	$18.92	+268.1%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RMTI vs RNAZ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RMTI vs RNAZ — Which Stock Is More Undervalued?

RMTI scores higher with a 6.0/10 quality rating vs RNAZ's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Rockwell Medical, Inc. (RMTI) and TransCode Therapeutics, Inc. (RNAZ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RMTI currently trades at $0.74 with a QOC of 6.0/10, while RNAZ trades at $5.14 with a QOC of 3.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).